These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11795388)

  • 21. Application of a yeast estrogen screen in non-biomarker species Varicorhinus barbatulus fish with two estrogen receptor subtypes to assess xenoestrogens.
    Fu KY; Chen CY; Chang WM
    Toxicol In Vitro; 2007 Jun; 21(4):604-12. PubMed ID: 17258427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
    Nagel SC; Hagelbarger JL; McDonnell DP
    Endocrinology; 2001 Nov; 142(11):4721-8. PubMed ID: 11606437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of caveolin-1 in human myometrial and uterine leiomyoma smooth muscle.
    Zhou Y; Ren Y; Cui L; Li Z; Zhu Y; Lin W; Wang Y
    Am J Obstet Gynecol; 2014 Nov; 211(5):496.e1-496.e13. PubMed ID: 24909339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen-associated genes in uterine leiomyoma.
    Li S; McLachlan JA
    Ann N Y Acad Sci; 2001 Dec; 948():112-20. PubMed ID: 11795389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
    Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
    J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture.
    Zava DT; Blen M; Duwe G
    Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):637-45. PubMed ID: 9168008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Estrogen induced rat model of uterine leiomyoma].
    Chen HG; Lan Z; Cui QC; Lang JH; Li B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):408-11. PubMed ID: 21906450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal action of plant derived and anthropogenic non-steroidal estrogenic compounds: phytoestrogens and xenoestrogens.
    Lóránd T; Vigh E; Garai J
    Curr Med Chem; 2010; 17(30):3542-74. PubMed ID: 20738246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xenoestrogens: mechanisms of action and detection methods.
    Mueller SO
    Anal Bioanal Chem; 2004 Feb; 378(3):582-7. PubMed ID: 14564443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of uterine calbindin-D9k through an estrogen receptor-dependent pathway following single injection with xenobiotic agents in immature rats.
    Dang VH; Choi KC; Hyun SH; Jeung EB
    J Toxicol Environ Health A; 2007 Jan; 70(2):171-82. PubMed ID: 17365578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor gene expression in human uterine leiomyomata.
    Brandon DD; Erickson TE; Keenan EJ; Strawn EY; Novy MJ; Burry KA; Warner C; Clinton GM
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1876-81. PubMed ID: 7775635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of uterine leiomyomas in CD-1 mice following developmental exposure to diethylstilbestrol (DES).
    Newbold RR; Moore AB; Dixon D
    Toxicol Pathol; 2002; 30(5):611-6. PubMed ID: 12371671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levels of estrogen and progesterone receptors in the myometrium and leiomyoma tissue after suppression of estrogens with gonadotropin releasing hormone analogs.
    van de Ven J; Sprong M; Donker GH; Thijssen JH; Mak-Kregar S; Blankenstein MA
    Gynecol Endocrinol; 2001 Dec; 15 Suppl 6():61-8. PubMed ID: 12227888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environmental xenoestrogens, antiandrogens and disorders of male sexual differentiation.
    Sultan C; Balaguer P; Terouanne B; Georget V; Paris F; Jeandel C; Lumbroso S; Nicolas J
    Mol Cell Endocrinol; 2001 Jun; 178(1-2):99-105. PubMed ID: 11403899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scientific issues associated with the validation of in vitro and in vivo methods for assessing endocrine disrupting chemicals.
    Ashby J
    Toxicology; 2002 Dec; 181-182():389-97. PubMed ID: 12505341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of metformin on the expression of estrogen synthetase and ER mRNA in uterine leiomyoma tissues].
    Wang SY; Xue Q; Zhou YF; Yin L
    Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):249-254. PubMed ID: 31006191
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
    Wu T; Chen X; Xie L
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005287. PubMed ID: 17943846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
    Lingxia X; Taixiang W; Xiaoyan C
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005287. PubMed ID: 17443581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of the estrogen receptor ratio in myometrium and uterine leiomyomas.
    Otsuka H; Shinohara M; Kashimura M; Yoshida K; Okamura Y
    Int J Gynaecol Obstet; 1989 Jun; 29(2):189-94. PubMed ID: 2568297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.